LUMO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LUMO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lumos Pharma's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lumos Pharma's Operating Income for the three months ended in Mar. 2024 was $ -10.86 Mil. Lumos Pharma's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Lumos Pharma's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Lumos Pharma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Pharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -0.05 | - | - | - | - |
Lumos Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Pharma (NAS:LUMO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Lumos Pharma's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-10.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.23 Mil.
Lumos Pharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
GuruFocus does not calculate Lumos Pharma's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Lumos Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.
David B Karpf | officer: Chief Medical Officer | 1360 WILLOW ROAD #100, MENLO PARK CA 94025 |
Aaron Schuchart | officer: Chief Business Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Joseph S Mccracken | director | C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000 |
Richard J Hawkins | director, officer: Chief Executive Officer | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Emmett Cunningham | director | C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134 |
Kevin M. Lalande | director | 201 WEST 5TH STREET, AUSTIN TX 78701 |
John C. Mckew | officer: Chief Scientific Officer | C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756 |
Deerfield Mgmt Iii, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Private Design Fund Iii, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Member of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Bradley J Powers | officer: Principal Executive Officer | C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Lori D Lawley | officer: Principal Accounting Officer | C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Ernest Iii Talarico | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
From GuruFocus
By Value_Insider Value_Insider • 11-22-2022
By Marketwired • 09-14-2023
By Stock market mentor Stock market mentor • 01-03-2023
By sperokesalga sperokesalga • 05-25-2023
By Marketwired • 08-09-2023
By Value_Insider Value_Insider • 11-29-2022
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-16-2022
By sperokesalga sperokesalga • 02-15-2023
By Marketwired • 07-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.